STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence
On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia (AML) — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said.
- The randomized Phase 3 study enrolled 367 patients with intermediate-risk bladder cancer, a localized form of the disease that is typically removed in a minimally invasive surgical procedure.
- Physicians use a catheter to infuse “creto” directly into the bladder, where it enters the mutated cancer cells, replicates rapidly, then breaks open the cells, killing them.
- If the cancer returns, repeat surgical procedures can be performed, but over time, patients lose bladder function and the cancer can continue to grow.
It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.
- Continue to STAT+ to read the full story….
- The CG Oncology treatment, called cretostimogene, is made from a type of common cold virus engineered to target cells that express a specific mutation found in bladder tumors.
- In a column published in September, I predicted galinpepimut would fail to prolong survival in the Phase 3 study.
- Patients are then monitored every three months.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →